Edition:
United Kingdom

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

15.35USD
15 Aug 2018
Change (% chg)

$-0.90 (-5.54%)
Prev Close
$16.25
Open
$16.20
Day's High
$16.27
Day's Low
$15.23
Volume
469,447
Avg. Vol
463,120
52-wk High
$27.50
52-wk Low
$9.73

Chart for

About

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company... (more)

Overall

Beta: 3.12
Market Cap(Mil.): $1,333.59
Shares Outstanding(Mil.): 83.61
Dividend: --
Yield (%): --

Financials

  SGMO.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.81 -- --
ROI: -28.31 1.78 14.61
ROE: -32.60 3.28 16.33

BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003

* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE

16 May 2018

BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23

* SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

26 Apr 2018

BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

24 Apr 2018

BRIEF-Sangamo Therapeutics Files For Potential Mixed Shelf Offering

* SANGAMO THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2vH7vVF) Further company coverage:

24 Apr 2018

BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior Executive's Company Email Account

* SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE'S COMPANY EMAIL ACCOUNT

17 Apr 2018

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion (2.16 billion pounds) to Sangamo, the companies said on Thursday.

22 Feb 2018

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

22 Feb 2018

UPDATE 2-Sangamo in $3 billion gene-editing deal with Gilead

* Sangamo stock jumps 21 percent (Adds CEO and executive quotes, background, updates share price)

22 Feb 2018

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Feb 22 Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

22 Feb 2018

Competitors

Earnings vs. Estimates